Interestingly, we observed a similar insensitivity to TH-302 with the prostate cancer model TRAMP-C2A with regard to tumor growth, which could be partially overcome when TH-302 was combined with VEGFR-2 blockade and thus shows the potential application of this combination therapy scheme across models. This evidence concerns the gene KDR and prostate carcinoma.